Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 13 Sept 2022 for Cidara Therapeutics, Inc., €11k. Read the official filing
Filing timeline
BuySalePaul Daruwala
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Paul Daruwala: trading record in brief
Paul Daruwala (senior executive) discloses dealings in Cidara Therapeutics, Inc. to SEC (Form 4). Between 30 September 2021 and 12 September 2022, the trades on record add up to 4 filings.
On the market, this insider has only sold: 1 sale, €11k in total. Other entries cover 2 share grants and 1 option exercise. 2022 to date brings no purchases and 1 sale.
The latest filing, published on 13 September 2022, reports an open-market sale of €11k in Cidara Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Paul Daruwala
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
16,199 shares@ US$0.6849100.0% of flowCommon StockSEC:0001610618-22-000076:0
50,000 shares0Common StockSEC:0001610618-22-000019:0
9,900 shares0Common StockSEC:0001209191-22-002604:0
132,000 shares0Common StockSEC:0001610618-21-000091:0
4 of 4 declarations
